Kyverna Therapeutics Presents First-In-Disease Use Of KYV-101 In Patient With Severe Stiff-Person Syndrome Published In Proceedings Of The National Academy Of Sciences
Portfolio Pulse from Benzinga Newsdesk
Kyverna Therapeutics announced the first use of KYV-101, an anti-CD19 CAR T-cell product, in a patient with severe stiff-person syndrome. The treatment showed significant improvement in walking distance and a 40% reduction in GABAergic medications, with low-grade side effects. This supports further exploration of KYV-101 in neuroimmunological diseases.
June 17, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kyverna Therapeutics' KYV-101 demonstrated significant clinical benefits in a patient with severe stiff-person syndrome, showing potential for further development in neuroimmunological diseases.
The positive clinical results and low-grade side effects of KYV-101 in treating a severe case of stiff-person syndrome suggest potential for further development and regulatory approval, likely boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100